Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioMed rTSST-1 Variant Vaccine in Healthy Adults
NCT02814708Phase 2Completed
- Sponsor
- Biomedizinische Forschung
- Start
- May 2016
- Primary completion
- May 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rTSST-1 variant vaccine in toxic shock syndrome (TSS), sponsored by Biomedizinische Forschung. Started May 2016; status: completed.
02
Drugs
rTSST-1 variant vaccine
03
Conditions
toxic shock syndrome (TSS)
Beyond the preview
Go deeper on NCT02814708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814708.